PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer

Medicine, Oncology, Life Sciences, Immunology,
breast cancer   radiation therapy   Pembrolizumab   neoadjuvant chemotherapy   biomarkers   HER2-negative   tumor-infiltrating lymphocytes  

Academic Background Breast cancer is one of the most common cancers among women worldwide, particularly triple-negative breast cancer (TNBC) and hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer, which are known for their aggressive nature and poor prognosis. In recent years, immune checkpoint inh...

A Prospective Study of Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma: The Keystone-001 Trial

Medicine, Oncology, Life Sciences, Cell Biology, Biochemistry, Immunology,
Esophageal Squamous Cell Carcinoma   Neoadjuvant Therapy   Pembrolizumab   Chemotherapy   Survival Rate  

Background and Research Motivation Esophageal Squamous Cell Carcinoma (ESCC) is a highly aggressive cancer, especially in locally advanced stages. Traditional neoadjuvant chemoradiotherapy (NCRT) is the standard treatment method for this type of cancer. Despite its significant therapeutic effects, local recurrence and distant metastasis rates remai...